{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=10", "query": { "intervention": "combined treatment", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 13959, "total_pages": 1396, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:34:51.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03535402", "title": "Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gaylis, Norman B., M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-06-01", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 1, "location_summary": "Aventura, Florida", "locations": [ { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535402" }, { "nct_id": "NCT00247195", "title": "Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Culturally Congruent Assessment and Treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 113, "start_date": "2005-11", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00247195" }, { "nct_id": "NCT01976169", "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "PD-0332991 and T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 29, "start_date": "2014-01-24", "completion_date": "2021-05-19", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976169" }, { "nct_id": "NCT00916669", "title": "A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "enoxaparin sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-08", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Peabody", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00916669" }, { "nct_id": "NCT02397954", "title": "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Polypoidal Choroidal Vasculopathy" ], "interventions": [ { "name": "Avacincaptad Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 4, "start_date": "2015-03-12", "completion_date": "2015-10-23", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397954" }, { "nct_id": "NCT02140554", "title": "A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "lovo-cel", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Genetix Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 54, "start_date": "2015-02-02", "completion_date": "2024-01-30", "has_results": true, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140554" }, { "nct_id": "NCT01490866", "title": "A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 12, "location_summary": "Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490866" }, { "nct_id": "NCT03092856", "title": "Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Anti-OX40 Antibody PF-04518600", "type": "BIOLOGICAL" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-07-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 9, "location_summary": "Los Angeles, California • Newport Beach, California • Sacramento, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03092856" }, { "nct_id": "NCT04459702", "title": "A Study of Combination Therapies to Treat COVID-19 Infection", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID", "COVID-19", "Corona Virus Infection", "Coronavirus Infection", "Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere", "Coronavirus-19", "SARS-CoV 2", "SARS Pneumonia" ], "interventions": [ { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Lopinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2020-07", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459702" }, { "nct_id": "NCT06109272", "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-01-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T12:34:51.910Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109272" } ] }